FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045347979> ?p ?o ?g. }

• W2045347979 endingPage "69" @default.
• W2045347979 startingPage "63" @default.
• W2045347979 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Jul 1996Role of Proliferative Activity Estimated by Bromodeoxyuridine Labeling Index in Determining Predictive Factors of Recurrence in Superficial Intermediately Malignant Bladder Tumors Masaaki Tachibana, Ayako Miyakawa, Kaoru Nakamura, Shiro Baba, Masaru Murai, and Hiroshi Tazaki Masaaki TachibanaMasaaki Tachibana More articles by this author , Ayako MiyakawaAyako Miyakawa More articles by this author , Kaoru NakamuraKaoru Nakamura More articles by this author , Shiro BabaShiro Baba More articles by this author , Masaru MuraiMasaru Murai More articles by this author , and Hiroshi TazakiHiroshi Tazaki More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65940-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Previous studies have shown that factors predictive of tumor recurrence include a history of the disease, multiple tumors at diagnosis, and high tumor grade and stage. Additional biological markers for predicting tumor recurrence could potentially be used in the decision making process and could alter the frequency of clinical cystoscopy. We attempted to clarify whether the tumor proliferative activity estimated by bromodeoxyuridine, which is believed to be a thymidine analogue, and deoxyribonucleic acid (DNA) ploidy status correlates well with tumor recurrence as an objective parameter. Materials and Methods: We evaluated 103 patients with superficial grade 2 transitional cell carcinoma of the bladder treated with transurethral resection. Mean followup plus or minus standard deviation was 49.5 plus/minus 11.3 months (minimum 36). Tumor specimens were obtained by transurethral cold-cup biopsy, with bromodeoxyuridine in vitro pulse labeling then performed under hyperbaric oxygen. The flow cytometric determination of the bromodeoxyuridine labeled cell index and DNA ploidy were estimated. Results: When the tumor was classified according to the bromodeoxyuridine labeled cell index the 5-year no recurrence rates were 82.0 and 27.1 percent for an index of less than 5.3 and more than 5.3 percent respectively. Furthermore, the 5-year no recurrence rates were 75.1 percent for DNA diploid compared to 29.3 percent for DNA aneuploid tumors, respectively. Multivariate analysis using Cox's proportional hazards model showed that the most important risk factor for tumor recurrence was a bromodeoxyuridine labeled cell index of more than 5.3 percent (risk ratio 5.31, p less than 0.001), followed by DNA ploidy (risk ratio 2.61, p less than 0.05). Tumor stage, initial lesion versus recurrence and single versus multiple tumors did not influence the risk factor for tumor recurrence. Conclusions: These data indicate that bromodeoxyuridine labeling status can be used as an objective risk factor for bladder cancer recurrence. References 1 : Developments in the pathology of bladder cancer. In: The Management of Bladder Cancer. Edited by . Baltimore: Edward Arnold1988: 42. chapt. 2. Google Scholar 2 : Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy. Urol. Clin. N. Amer.1992; 19: 485. Google Scholar 3 : In vivo administration of bromodeoxyuridine and flow cytometry for cell kinetic studies in human malignancies. Haematologica1987; 72: 115. Google Scholar 4 : Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci.1983; 80: 5573. Google Scholar 5 : S phase fraction of human bladder tumor measured in situ with bromodeoxyuridine labeling. J. Urol.1988; 139: 286. Link, Google Scholar 6 : Quantification of cell kinetic characteristics using flow cytometric measurements of deoxyribonucleic acid and bromodeoxyuridine for bladder cancer. J. Urol.1991; 145: 963. Link, Google Scholar 7 : Prognostic significance of bromodeoxyuridine high labeled bladder cancer measured by flow cytometry: does flow cytometric determination predict the prognosis of patients with transitional cell carcinoma of the bladder. J. Urol.1993; 149: 739. Link, Google Scholar 8 : TNM Classification of Malignant Tumours. Geneva: International Union Against Cancer1978. Google Scholar 9 : Tumors of the urinary bladder. Atlas of Tumor Pathology. Washington, D. C.: Armed Forces Institute of Pathology1975. 2nd series, fasc. 11. Google Scholar 10 : Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. J. Histochem. Cytochem.1978; 26: 921. Google Scholar 11 : Urothelial tumors of the urinary tract. In: . Philadelphia: W. B. Saunders Co1992: 1094. chapt. 28. Google Scholar 12 : Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J. Urol.1986; 135: 920. Link, Google Scholar 13 : Superficial bladder cancer: progression and recurrence. J. Urol.1983; 130: 1083. Link, Google Scholar 14 : diagnostic factors in superficial bladder tumors. A study of the European Organization for Research on the Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J. Urol.1983; 129: 730. Abstract, Google Scholar 15 : DNA pattern, histological grade and multiplicity related to recurrence rate in superficial bladder tumours. Scand. J. Urol. Nephrol.1982; 16: 135. Google Scholar 16 : DNA profile and tumour progression in patients with superficial bladder tumours. Urol. Res.1982; 10: 13. Google Scholar 17 : The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Amer. J. Clin. Path.1989; 91: 243. Google Scholar 18 : Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J. Urol.1991; 146: 1525. Link, Google Scholar 19 : Multivariate analysis of flow cytometric deoxyribonucleic acid parameters and histological features for prognosis of bladder cancer patients. J. Urol.1991; 146: 1530. Link, Google Scholar 20 : Growth and cell kinetic measurements in human tumors. Path. Ann., part 21981; 16: 53. Google Scholar 21 : The role of flow cytometry in urologic oncology. In: Genitourinary Cancer. Edited by . Boston: Martinus Nijhoff Publishers1987: 241. chapt. 11. Google Scholar 22 : Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science1982; 218: 474. Google Scholar 23 : Comparative study of proportion of S-phase cells in ascites and pleural effusions in ovarian carcinoma using antibromodeoxyuridine monoclonal antibody and DNA flow-cytometry. Acta Oncol.1989; 28: 705. Google Scholar 24 : Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors. J. Neurosurg.1989; 70: 379. Google Scholar 25 : Flow cytometric determination of modal DNA population in relation to proliferative potential of human intracranial neoplasms. J. Neurosurg.1988; 69: 588. Google Scholar 26 : Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci.1993; 90: 8287. Google Scholar 27 : Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif.1993; 26: 67. Google Scholar 28 : 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder. Mod. Path.1993; 6: 20. Google Scholar 29 : New Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab. Invest.1993; 68: 629. Google Scholar 30 : The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J. Urol.1993; 149: 272. Google Scholar 31 : Cell proliferation indices, morphometry and DNA flow cytometry provide objective criteria for distinguishing low and high grade bladder carcinomas. Virchows Arch.1994; 424: 143. Google Scholar Department of Urology, School of Medicine, Keio University, Tokyo, Japan.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 156Issue 1July 1996Page: 63-69 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Masaaki Tachibana More articles by this author Ayako Miyakawa More articles by this author Kaoru Nakamura More articles by this author Shiro Baba More articles by this author Masaru Murai More articles by this author Hiroshi Tazaki More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2045347979 created "2016-06-24" @default.
• W2045347979 creator A5006511872 @default.
• W2045347979 creator A5018631757 @default.
• W2045347979 creator A5020251887 @default.
• W2045347979 creator A5071174564 @default.
• W2045347979 creator A5076637619 @default.
• W2045347979 creator A5089388893 @default.
• W2045347979 date "1996-07-01" @default.
• W2045347979 modified "2023-10-16" @default.
• W2045347979 title "Role of Proliferative Activity Estimated by Bromodeoxyuridine Labeling Index in Determining Predictive Factors of Recurrence in Superficial Intermediately Malignant Bladder Tumors" @default.
• W2045347979 cites W1975874660 @default.
• W2045347979 cites W1991530149 @default.
• W2045347979 cites W2014393519 @default.
• W2045347979 cites W2031468048 @default.
• W2045347979 cites W2032448671 @default.
• W2045347979 cites W2033154667 @default.
• W2045347979 cites W2041489150 @default.
• W2045347979 cites W2054547141 @default.
• W2045347979 cites W2055478303 @default.
• W2045347979 cites W2128444068 @default.
• W2045347979 cites W2150067782 @default.
• W2045347979 cites W2307377078 @default.
• W2045347979 cites W2331123264 @default.
• W2045347979 cites W2395028327 @default.
• W2045347979 cites W2402487223 @default.
• W2045347979 cites W2411310297 @default.
• W2045347979 cites W2413672670 @default.
• W2045347979 cites W2415472467 @default.
• W2045347979 cites W2420271570 @default.
• W2045347979 cites W2472398971 @default.
• W2045347979 cites W317249572 @default.
• W2045347979 cites W4298350592 @default.
• W2045347979 doi "https://doi.org/10.1016/s0022-5347(01)65940-8" @default.
• W2045347979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8648839" @default.
• W2045347979 hasPublicationYear "1996" @default.
• W2045347979 type Work @default.
• W2045347979 sameAs 2045347979 @default.
• W2045347979 citedByCount "7" @default.
• W2045347979 countsByYear W20453479792012 @default.
• W2045347979 crossrefType "journal-article" @default.
• W2045347979 hasAuthorship W2045347979A5006511872 @default.
• W2045347979 hasAuthorship W2045347979A5018631757 @default.
• W2045347979 hasAuthorship W2045347979A5020251887 @default.
• W2045347979 hasAuthorship W2045347979A5071174564 @default.
• W2045347979 hasAuthorship W2045347979A5076637619 @default.
• W2045347979 hasAuthorship W2045347979A5089388893 @default.
• W2045347979 hasConcept C142724271 @default.
• W2045347979 hasConcept C204232928 @default.
• W2045347979 hasConcept C2778260397 @default.
• W2045347979 hasConcept C71924100 @default.
• W2045347979 hasConceptScore W2045347979C142724271 @default.
• W2045347979 hasConceptScore W2045347979C204232928 @default.
• W2045347979 hasConceptScore W2045347979C2778260397 @default.
• W2045347979 hasConceptScore W2045347979C71924100 @default.
• W2045347979 hasIssue "1" @default.
• W2045347979 hasLocation W20453479791 @default.
• W2045347979 hasLocation W20453479792 @default.
• W2045347979 hasOpenAccess W2045347979 @default.
• W2045347979 hasPrimaryLocation W20453479791 @default.
• W2045347979 hasRelatedWork W1506200166 @default.
• W2045347979 hasRelatedWork W1995515455 @default.
• W2045347979 hasRelatedWork W2048182022 @default.
• W2045347979 hasRelatedWork W2080531066 @default.
• W2045347979 hasRelatedWork W2604872355 @default.
• W2045347979 hasRelatedWork W2748952813 @default.
• W2045347979 hasRelatedWork W2899084033 @default.
• W2045347979 hasRelatedWork W3031052312 @default.
• W2045347979 hasRelatedWork W3032375762 @default.
• W2045347979 hasRelatedWork W3108674512 @default.
• W2045347979 hasVolume "156" @default.
• W2045347979 isParatext "false" @default.
• W2045347979 isRetracted "false" @default.
• W2045347979 magId "2045347979" @default.
• W2045347979 workType "article" @default.